Emerging Mechanisms and Therapeutic Targets in Liver Fibrogenesis
Nov
2026
Description
This session focuses on emerging mechanisms of liver fibrogenesis and novel antifibrotic therapeutic strategies. Topics include hepatic stellate cell activation, extracellular matrix remodeling, metabolic and epigenetic regulation of fibrosis, and innovative cell- and RNA-based therapies. Through mechanistic and translational studies, speakers will highlight new opportunities to prevent, halt, and reverse liver fibrosis.
Presentations
8:00 AM
- 8:15 AM
Convention Center - Bluebird Ballroom 3DEF
Human liver progenitor cell-derived extracellular vesicles drive convergent antifibrotic responses through model-distinct immune remodeling in murine MASH
Moira B. Hilscher, MD | Abstract Presenter
8:30 AM
- 8:45 AM
Convention Center - Bluebird Ballroom 3DEF
siRNA-Mediated GLT25D1 Silencing Attenuates Liver Fibrosis via Impairment of Collagen O-Glycosylation, ER Retention, and Degradation of Misfolded Procollagen
Scott Friedman, MD | Abstract Presenter
9:00 AM
- 9:15 AM
Convention Center - Bluebird Ballroom 3DEF
Spatial epigenomics, in vivo CRISPRi, and 13C6-glucose tracing reveal glycolysis-to-histone acetylation to drive hepatic stellate cell activation and subsequent murine and human liver fibrosis
Moira B. Hilscher, MD | Abstract Presenter
9:15 AM
- 9:30 AM
Convention Center - Bluebird Ballroom 3DEF
Cirrhotic liver extracellular matrix reveals matrisome remodeling and serves as a scaffold for advanced human in vitro models
Scott Friedman, MD | Abstract Presenter
